Related Articles
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)
Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)
Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC
Role of programmed death ligands in effective T‑cell interactions in extranodal natural killer/T‑cell lymphoma
Liquid biopsy for lung cancer immunotherapy (Review)